17,261 trials
Pulmonary Arterial Hypertension
Primary: Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 24, as Measured by Right Heart Catheterization (RHC) — 35; -28; -21; 6 dyne*sec/cm^5 — p== 0.214
Cocaine Dependence
Primary: Number of Cocaine Non-use Days — 10.1; 17.1; 9.3; 14.1 Number of Days
Preeclampsia
Primary: Number of Participants With Persistent Postpartum Hypertension Defined as Systolic Blood Pressure ≥ 150 and/or Diastolic Blood Pressure ≥ 100 mmHg — 26; 34 Participants
Physical Activity
Primary: Mitochondrial Function — 7.1; 43.2; 15.6; 13.8 percent change in pmol/s/mg tissue
Ventricular Arrhythmia
Primary: Overall Occurrence (Total Number) of Appropriate Implantable Cardioverter-Defibrillator Device (ICD) Interventions (Anti-Tachycardia Pacing or Shock) Through Week 24…
Erectile Dysfunction
Primary: Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF) Erectile Function (EF) Domain Score — 2.515; 2.405; -0.971; 3.530 units on a…
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Association of Baseline FMISO PET and MRI Features With OS as Assessed Using Cox-regression Model — 25; 22; 24; 20 Participants — p=0.048
Lupus Nephritis
Primary: Percentage of Participants With At Least One Grade 3 or Higher Infectious Adverse Event By Week 24, Week 48 and Week 96 — 9.1; 4.8; 22.7; 9.5 percentage of participants…
Opioid-Induced Constipation
Primary: Change From Baseline in 8-Week SBM Frequency Rate (SBMs/Week) — 1.474; 2.799; 3.382 Number of SBMs per week — p=0.0035
Multiple Myeloma
Primary: Maximum Tolerated Dose (MTD) of Carfilzomib and Pegylated Liposomal Doxorubicin (Phase I - Part 1). — 56; 30 mg/m^2
Influenza
Primary: CD4+ and CD8+ Th1 Cellular Immunogenicity on Day 42 — 0.5; 5.9; 1.0; 0.2 fold change — p=0.45
Glioblastoma Multiforme
Primary: Percentage of Participants With Progression Free Survival at 6 Months (PFS-6) — 53.6 percentage of participants
Dry Eye Syndromes
Primary: Change From Baseline in Conjunctival Redness Score in the Study Eye Using a 5-Point Scale — 1.9; 2.2; 2.0; 2.1 score on a scale
AL Amyloidosis
Primary: Number of Participants With Cardiac Response and Non-Response — 26; 30; 40; 33 Participants — p=0.3190
Atopic Dermatitis
Primary: Percent Change From Baseline in EASI Score in Cohort 3 — -34.24; -34.29; -34.04; -31.03 percent change from baseline in EASI — p=0.5016